Theravance Biopharma (NASDAQ:TBPH) Releases Quarterly Earnings Results, Misses Estimates By $0.16 EPS

Theravance Biopharma (NASDAQ:TBPH) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.16), Zacks reports. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.23%. The firm had revenue of $16.87 million for the quarter, compared to the consensus estimate of $16.11 million. During the same period in the prior year, the business earned ($0.17) EPS.

Theravance Biopharma Stock Up 11.0 %

TBPH traded up $0.98 during trading on Wednesday, hitting $9.89. The company’s stock had a trading volume of 187,885 shares, compared to its average volume of 345,884. The firm’s 50 day moving average price is $8.32 and its two-hundred day moving average price is $8.68. Theravance Biopharma has a 12 month low of $7.44 and a 12 month high of $11.71. The stock has a market capitalization of $483.84 million, a price-to-earnings ratio of -9.92 and a beta of 0.25.

Analyst Ratings Changes

TBPH has been the subject of a number of recent analyst reports. TD Cowen decreased their price target on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Monday, September 16th. Leerink Partnrs downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Leerink Partners downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $15.00 to $10.00 in a research note on Tuesday, August 6th. Finally, StockNews.com downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $13.75.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.